

Buchanan Ingersoll
ATTORNEYS

1776 K Street, N.W.
Suite 800
Washington, DC 20006-2365

Edward John Allera
(202) 452-7985
alleraej@bipc.com

T 202 452 7900
F 202 452 7989
www.buchananingersoll.com

24
7
03
NOV 14
PM 2:23

November 14, 2003

VIA HAND DELIVERY

Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Re: Correction to November 6, 2003 Submission to Docket No. 2003N-0324

To Whom it May Concern:

On November 6, 2003 Pennfield Oil Company/Pennfield Animal Health ("Pennfield") submitted materials supporting the company's requests for hearing for New Animal Drug Application ("NADA") 141-137 (Pennitracin MD 50-G™) and NADA 138-939 (NEO-OXY™). Requests for hearing for both products were filed on September 8, 2003, in response to FDA's August 8, 2003 Notice of Opportunity for Hearing.


At this time we are making several minor corrections to the two cover letters that were submitted on November 6, 2003 - one for NADA 141-137 and one for NADA 138-939.

In the cover letter for NADA 141-137, in the first paragraph of page 2, the sentence beginning in line two should begin, "In September of 1998,...." In this same paragraph, line 6, the line should begin with the phrase "indications now in dispute." Also in line 6 of this same paragraph, the sentence beginning on that line should begin, "On December 9, 1998,...."

In the cover letter for NADA 138-939, we misidentified the NADA number of the product as 138-139. This misstatement occurred in the "Re:" line of the letter, as well as in the second last line of paragraph one.

We would like these errata to both of our November 6, 2003 cover letters to appear in Docket No. 2003N-0324.

Sincerely,



Edward John Allera
Counsel to Pennfield Oil Company/
Pennfield Animal Health

2003N-0324

CR 2